MPAL: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
<div style="width: 95%"; font-size:90%> | <div style="width: 95%"; font-size:90%> | ||
{| class="wikitable" | {| class="wikitable" | ||
!colspan="2" style = "background:lightgrey; border:solid"| '''Frequency of MPAL types'''</br>Not all forms of MPAL occur with the same | !colspan="2" style = "background:lightgrey; border:solid"| '''Frequency of MPAL types'''</br>Not all forms of MPAL occur with the same frequency, the following types are regognised. | ||
|- | |- | ||
!colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with features of Myeloid and B-lineage | !colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with features of Myeloid and B-lineage | ||
!colspan="1" style = "background:white;border:solid; font-size:90%;"| | !colspan="1" style = "background:white;border:solid; font-size:90%;"| This is the most common MPAL (more than 50% of cases). | ||
|- | |- | ||
!colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with features of Myeloid and T-lineage | !colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with features of Myeloid and T-lineage | ||
!colspan="1" style = "background:white; border:solid; font-size:90%;"| | !colspan="1" style = "background:white; border:solid; font-size:90%;"| The second most frequent form (over one third of cases). I | ||
|- | |- | ||
!colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with | !colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with combinations: T- and B- +/-myeloid-lineage | ||
!colspan="1" style = "background:white; border:solid; font-size:90%;"| | !colspan="1" style = "background:white; border:solid; font-size:90%;"| These forms are infrequent (around 10% of cases) | ||
|- | |- | ||
!colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with defining molecular features | !colspan="1" style = "background:#FFFFF0;border:solid"| MPAL with defining molecular features |
Revision as of 19:20, 22 November 2023
Important Note
Flow cytometry provides initial evidence of MPAL. However conclusions may subsequently be modified (e.g. by results of immunohistochemistry, cytogenetics, or genetics). It is important that the provisional nature of flow cytometry assignment of MPAL is acknowledged when making a flow cytometric diagnosis of MPAL.
Frequency of MPAL types Not all forms of MPAL occur with the same frequency, the following types are regognised. | |
---|---|
MPAL with features of Myeloid and B-lineage | This is the most common MPAL (more than 50% of cases). |
MPAL with features of Myeloid and T-lineage | The second most frequent form (over one third of cases). I |
MPAL with combinations: T- and B- +/-myeloid-lineage | These forms are infrequent (around 10% of cases) |
MPAL with defining molecular features | Following further analysis cases may be assigned additionally as: MPAL with t(9;22) (q34.1;q11.2); BCR-ABL1), MPAL with t(v;11q23.3); with KMT2A re-arrangement |
.
Requirements to assign myeloid lineage in MPAL
| |
---|---|
Marker option 1 | |
Demonstrate expression of Myeloperoxidase (MPO) | Myeloperoxidase expression alone may be sufficient to establish myeloid lineage, but be aware of the limitations: (1) intensity should be at least half of that of mature neutrophils in at least of proportion of cells measured by the same method; (2) there are circumstances where judgement is required (see notes). |
Marker option 2 | |
Demonstrate clear evidence of monocytic lineage | If MPO is not demonstrated then myeloid lineage may still be assigned through demonstration of monocytic features. This can be assigned by the detection of at least two of the following features: By flow cytometry: CD11c, CD14, CD64; by other approaches: lysozyme or non-specific esterase in malignant cells (enzyme cytochemistry) |
.
NOTE Interpretation of MPO positivity in MPAL
1. The techniques used to detect MPO do not have the same sensitivity: immunohistochemistry > flow cytometry > enzyme-cytochemistry. This means diagnosis of MPAL may be method dependent – expressing MPO as intensity allows expression to be compared with that of normal cells detected using the same method.
|
---|
.
Requirements to assign B-lymphoid lineage in MPAL
| |
---|---|
Marker option 1 | |
Required Strong expression of CD19 | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal B lymphocytes |
In addition 1 of: CD10, CD22, or CD79a (surface or cytoplasmic) | If CD19 is strong then B-lineage can be assigned if there is at least ONE of these additional markers |
Marker option 2 | |
Required Weak expression of CD19 | To meet the definition of "weak" the expression intensity must be less than that of 50% of normal B lymphocytes |
In addition 2 of: CD10, CD22, or CD79a (surface or cytoplasmic) | If CD19 is weak then B-lineage can be assigned only if there are at least TWO of these additional markers |
.
Requirements to assign T-lymphoid lineage in MPAL
| |
---|---|
Marker requirement | |
Either CD3 surface or cytoplasm (strong) | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal T lymphocytes |
Or CD3 by immunocytochemistry (strong) | For immunohistochemistry it is important a non-zeta chain reagent is used |